|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Forastiere A, Koch W, Trotti A and
Sidransky D: Head and neck cancer. N Engl J Med. 345:1890–1900.
2001. View Article : Google Scholar
|
|
3
|
Capote A, Escorial V, Muñoz-Guerra MF,
Rodríguez-Campo FJ, Gamallo C and Naval L: Elective neck dissection
in early-stage oral squamous cell carcinoma - does it influence
recurrence and survival? Head Neck. 29:3–11. 2007. View Article : Google Scholar
|
|
4
|
Kowalski LP, Bagietto R, Lara JR, Santos
RL, Silva JF Jr and Magrin J: Prognostic significance of the
distribution of neck node metastasis from oral carcinoma. Head
Neck. 22:207–214. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lothaire P, de Azambuja E, Dequanter D,
Lalami Y, Sotiriou C, Andry G, Castro G Jr and Awada A: Molecular
markers of head and neck squamous cell carcinoma: Promising signs
in need of prospective evaluation. Head Neck. 28:256–269. 2006.
View Article : Google Scholar
|
|
6
|
Lopes MA, Nikitakis NG, Reynolds MA, Ord
RA and Sauk J Jr: Biomarkers predictive of lymph node metastases in
oral squamous cell carcinoma. J Oral Maxillofac Surg. 60:142–147;
discussion 147–148. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kahn HJ and Marks A: A new monoclonal
antibody, D2-40, for detection of lymphatic invasion in primary
tumors. Lab Invest. 82:1255–1257. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schacht V, Ramirez MI, Hong YK, Hirakawa
S, Feng D, Harvey N, Williams M, Dvorak AM, Dvorak HF, Oliver G, et
al: T1alpha/podoplanin deficiency disrupts normal lymphatic
vasculature formation and causes lymphedema. EMBO J. 22:3546–3556.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Durchdewald M, Guinea-Viniegra J, Haag D,
Riehl A, Lichter P, Hahn M, Wagner EF, Angel P and Hess J:
Podoplanin is a novel fos target gene in skin carcinogenesis.
Cancer Res. 68:6877–6883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shimada Y, Ishii G, Nagai K, Atsumi N,
Fujii S, Yamada A, Yamane Y, Hishida T, Nishimura M, Yoshida J, et
al: Expression of podoplanin, CD44, and p63 in squamous cell
carcinoma of the lung. Cancer Sci. 100:2054–2059. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dumoff KL, Chu CS, Harris EE, Holtz D, Xu
X, Zhang PJ and Acs G: Low podoplanin expression in pretreatment
biopsy material predicts poor prognosis in advanced-stage squamous
cell carcinoma of the uterine cervix treated by primary radiation.
Mod Pathol. 19:708–716. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chuang WY, Yeh CJ, Wu YC, Chao YK, Liu YH,
Tseng CK, Chang HK, Liu HP and Hsueh C: Tumor cell expression of
podoplanin correlates with nodal metastasis in esophageal squamous
cell carcinoma. Histol Histopathol. 24:1021–1027. 2009.PubMed/NCBI
|
|
13
|
Rahadiani N, Ikeda J, Makino T, Tian T,
Qiu Y, Mamat S, Wang Y, Doki Y, Aozasa K and Morii E: Tumorigenic
role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg
Oncol. 17:1311–1323. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan P, Temam S, El-Naggar A, Zhou X, Liu
DD, Lee JJ and Mao L: Overexpression of podoplanin in oral cancer
and its association with poor clinical outcome. Cancer.
107:563–569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawaguchi H, El-Naggar AK,
Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong
WK, Lippman SM, et al: Podoplanin: A novel marker for oral cancer
risk in patients with oral premalignancy. J Clin Oncol. 26:354–360.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Byrd DR, Compton CC, Fritz AG, Greene FL
and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer;
New York, NY: 2009
|
|
17
|
Koo BS, Kim JM, Seo ST, Yoon YH, Kwon KR,
Kim SH, Kwon HW, Bae WJ and Lim YC: Upregulation of HGF and c-MET
is associated with subclinical central lymph node metastasis in
papillary thyroid microcarcinoma. Ann Surg Oncol. 21:2310–2317.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang YH, Ji NY, Han SR, Lee CI, Kim JW,
Yeom YI, Kim YH, Chun HK, Kim JW, Chung JW, et al: ESM-1 regulates
cell growth and metastatic process through activation of NF-κB in
colorectal cancer. Cell Signal. 24:1940–1949. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schoppmann SF, Birner P, Studer P and
Breiteneder-Geleff S: Lymphatic microvessel density and
lymphovascular invasion assessed by anti-podoplanin immunostaining
in human breast cancer. Anticancer Res. 21:2351–2355.
2001.PubMed/NCBI
|
|
20
|
Raica M, Cimpean AM and Ribatti D: The
role of podoplanin in tumor progression and metastasis. Anticancer
Res. 28:2997–3006. 2008.PubMed/NCBI
|
|
21
|
Tomita N, Matsumoto T, Hayashi T, Arakawa
A, Sonoue H, Kajiyama Y and Tsurumaru M: Lymphatic invasion
according to D2-40 immunostaining is a strong predictor of nodal
metastasis in superficial squamous cell carcinoma of the esophagus:
Algorithm for risk of nodal metastasis based on lymphatic invasion.
Pathol Int. 58:282–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schacht V, Dadras SS, Johnson LA, Jackson
DG, Hong YK and Detmar M: Up-regulation of the lymphatic marker
podoplanin, a mucin-type transmembrane glycoprotein, in human
squamous cell carcinomas and germ cell tumors. Am J Pathol.
166:913–921. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Erovic BM, Neuchrist C, Kandutsch S,
Woegerbauer M and Pammer J: CD9 expression on lymphatic vessels in
head and neck mucosa. Mod Pathol. 16:1028–1034. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo
T and Osawa M: Enhanced expression of Aggrus (T1alpha/podoplanin),
a platelet-aggregation-inducing factor in lung squamous cell
carcinoma. Tumour Biol. 26:195–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kimura N and Kimura I: Podoplanin as a
marker for mesothelioma. Pathol Int. 55:83–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shibahara J, Kashima T, Kikuchi Y, Kunita
A and Fukayama M: Podoplanin is expressed in subsets of tumors of
the central nervous system. Virchows Arch. 448:493–499. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wicki A, Lehembre F, Wick N, Hantusch B,
Kerjaschki D and Christofori G: Tumor invasion in the absence of
epithelial-mesenchymal transition: Podoplanin-mediated remodeling
of the actin cytoskeleton. Cancer Cell. 9:261–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kreppel M, Scheer M, Drebber U, Ritter L
and Zöller JE: Impact of podoplanin expression in oral squamous
cell carcinoma: Clinical and histopathologic correlations. Virchows
Arch. 456:473–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tong L, Yuan S, Feng F and Zhang H: Role
of podoplanin expression in esophageal squamous cell carcinoma: A
retrospective study. Dis Esophagus. 25:72–80. 2012. View Article : Google Scholar
|
|
30
|
Rodrigo JP, García-Carracedo D, González
MV, Mancebo G, Fresno MF and García-Pedrero J: Podoplanin
expression in the development and progression of laryngeal squamous
cell carcinomas. Mol Cancer. 9:482010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martín-Villar E, Megías D, Castel S,
Yurrita MM, Vilaró S and Quintanilla M: Podoplanin binds ERM
proteins to activate RhoA and promote epithelial-mesenchymal
transition. J Cell Sci. 119:4541–4553. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cueni LN, Hegyi I, Shin JW, Albinger-Hegyi
A, Gruber S, Kunstfeld R, Moch H and Detmar M: Tumor
lymphangiogenesis and metastasis to lymph nodes induced by cancer
cell expression of podoplanin. Am J Pathol. 177:1004–1016. 2010.
View Article : Google Scholar : PubMed/NCBI
|
